ClinicalTrials.gg
Enrolling by invitationNCT05082077Updated Sep 17, 2026

Global Utilization And Registry Database for Improved preservAtion of doNor Livers

An observational study in Liver Diseases, Liver Dysfunction and Liver Transplant Disorder, sponsored by Paragonix Technologies. Enrolling by invitation at 15 sites in United States. Per ClinicalTrials.gov, last updated 2026-09-17.

Sponsored by Paragonix Technologies · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
2,000
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 369 studies in Liver Diseases with a site in United States — 46 open to participants now, 60 under way, 5 of them phase 3. Liver Diseases · United States.

Planned enrollment
8th of 90
2,000 · median 153
Started
2022
with 24 others
Observational
91 of 369
23 open now
Primary completion
2027-08
later than 18 of 58 live
Registered
284th of 369
by date

Among the 369 studies in Liver Diseases with a site in United States, this one is the 8th largest by planned enrollment of the 90 observational ones that give a count, is one of 25 that started in 2022, is one of 91 observational ones, reaches primary completion later than 18 of the 58 other live ones, and was the 284th registered.

Liver Diseases

825 studies on the registry are indexed under Liver Diseases; 153 are open to participants now.

Browse Liver Diseases studies →

Open to participants now

46 of the 369 studies in Liver Diseases with a site in United States are open now. Recruiting first, the newest first:

41 more — sign in →

All 46 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 105 Liver Diseases studies recruiting now, 52 (50%) set no upper age limit and 30 (29%) stop at 75 or younger; 20 take children under 18; 19 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 369 studies in Liver Diseases with a site in United States, or all of them as a file.
02

Study summary

The objective of this registry is to collect and evaluate various clinical effectiveness parameters in patients with transplanted donor liver that were preserved and transported within the LIVERguard system, as well as retrospective standard of care patients

Read the detailed description

GUARDIAN-Liver is a post-market, observational registry of adult and pediatric liver transplant recipient patients whose donor liver was preserved and transported within the LIVERguard. The data is being collected retrospectively from medical records of patients already transplanted before the initiation of the registry and any new patients who meet the eligibility criteria.

About 2,000 male and female subjects meeting the study inclusion and exclusion criteria will be enrolled into the study at about 20 clinical sites.

Candidates that fit the eligibility criteria and have had their donor liver transported with a Paragonix product or a standard of care method can be enrolled. The baseline characteristics and outcomes of the two groups will be compared.

03

Conditions studied

  • Liver Diseases
  • Liver Dysfunction
  • Liver Transplant Disorder
  • Liver Transplant Rejection

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients who have received a liver transplant at centers that use the LIVERguard device

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Donor and donor liver matched to the recipient based upon institutional medical practice
  • Registered male or female liver transplant candidates

Exclusion criteria

Exclusion Criteria:

  • Donor and donor liver that do not meet institutional clinical requirements for transplantation
  • Living donors
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
2,000 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes

Groups and cohorts

  • LIVERguard patient

    Patients whose donor liver was transported with the LiverGuard device.

    Device: LIVERguard

  • Standard Transport Patients

    Patients whose donor liver was transported with a method other than the LiverGuard

Interventions

  • DeviceLIVERguard

    The LIVERguard is an FDA cleared and is a CE-marked medical device intended to be used for the static hypothermic preservation of livers during transportation and eventual transplantation into a recipient using cold storage solutions indicated for use with the liver. The intended organ storage time for the LIVERguard is up to 16 hours.

06

What researchers measure

Primary outcomes

  1. Graft Failure

    The percentage of subjects in each cohort who develop graft failure post-transplant

    Time frame: Post-transplant through 1 year post

  2. Early allograft dysfunction

    The percentage of subjects in each cohort who early allograft failure post-transplant

    Time frame: 7 days post transplant

  3. Rejection

    The percentage of subjects in each cohort who experience rejection post-transplant

    Time frame: Post-transplant through 1 year post

  4. Primary Non-function

    The percentage of subjects in each cohort who experience primary non-function post-transplant

    Time frame: Post transplant to 7 days post-transplant

  5. Survival

    The percentage of subjects in each cohort who survive through 1 year post-transplant

    Time frame: Transplant through 1 year post-transplant

  6. Length of Stay

    How many days the patient stays in the hospital post-transplant

    Time frame: 1 year

  7. Length of ICU stay

    How many days the patient stayed in the ICU post-transplant

    Time frame: 1 year

Secondary outcomes

  1. Hospitalizations

    Amount of times patient is rehospitalized after discharge post-transplant

    Time frame: post-transplant through 1 year

  2. Biliary complications

    Percentage of patients that experience biliary strictures in each cohort as determined by lab work

    Time frame: post-transplant through 1 year post-transplant

07

Study locations

15 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2022 (actual). Primary completion is estimated for Aug 2027, 65 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2021
First posted
Oct 18, 2021
StartActual
Mar 15, 2022
Primary completionEst.
Aug 2027
CompletionEst.
Jan 2028
Last update
Sep 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05082077
Lead sponsor
Paragonix Technologies
Responsible party
Sponsor
First posted
Oct 18, 2021
Start date
Mar 15, 2022
Primary completion
Aug 2027 (estimated)
Completion
Jan 2028 (estimated)
Last update
Sep 17, 2026

Study contacts

Jason Vanatta, MD
principal investigator · Methodist Le Bonheur Healthcare

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion